Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that ...

Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Tampa’s Moffitt Cancer Center is forging an international partnership with Japan’s largest CRO, CMIC, to improve the ability ...

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

Mendaera has raised $73 million in venture capital funding to continue the development of its handheld robotics platform for ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

The NIH has found evidence of research misconduct against Eliezer Masliah, M.D., the longtime head of the National Institute ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

Listening to music while working may one day become a two-way street. | Neurable is putting forward a pair of headphones ...

While Windtree Therapeutics has struggled to grow the financial roots needed to survive, a phase 2 win for the biotech’s lead ...

Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...